PARP Inhibitors in Advanced Prostate Cancer C...

NMIBC Treatment Landscape (Republished) Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Janet Kukreja, MD, MPH, FACS CME Available: https://cme.auanet.org/URL/GUPOD253 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstraZeneca Johnson & Johnson LEARNING OB ...  Show more

MIBC Treatment Landscape (Republished) Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Jen-Jane Liu, MD, FACS CME Available: https://cme.auanet.org/URL/GUPOD252 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstraZeneca Johnson & Johnson LEARNING OBJECTIVE ...  Show more

Send a textNinja Nerds!In this episode of the Ninja Nerd Podcast, Zach and Rob break down the essential clinical and pathophysiologic features of Prostate Cancer, one of the most common malignancies affecting men worldwide.We begin with the epidemiology and risk factors, highligh ...  Show more

In this interview recorded at UROonco24 in Budapest earlier in the year, Dr. Gianluca Giannarini (IT) talks with Prof. Geert De Meerleer (BE) about the quality of life for patients with metastatic prostate cancer (mPCa) that are undergoing treatment. Their conversation feature ...

Prostate cancer diagnostic guidelines aim to minimize over-diagnosis of clinically insignificant prostate cancer (Gleason6/GG1). The clinical question before us is how do we enable the best balance, helping to increase compliance with the biopsy recommendation for patients at hig ...  Show more

View the Show Notes Page for This Episode

<a href= "https://peterattiamd.com/subscribe/ ...